Skip to content

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

Source
19 items
National Eye Institute

Avastin as effective as Eylea for treating central retinal vein occlusion

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI)...
Patient undergoes and eye exam. Courtesy National Eye Institute.

Eylea Outperforms Avastin for Diabetic Macular Edema with Moderate or Worse Vision Loss

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab).
NEI image using a slit lamp

New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes

This National Diabetes Month, there is some good news for people with eye complications from diabetes.
Animation of abnormal blood vessels bleeding into the center of the eye due to proliferative diabetic retinopathy. Photo credit: National Eye Institute. Watch video.

Lucentis Effective for Proliferative Diabetic Retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy.
Illustration showing the retina as seen through a dilated pupil.

Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss

In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse.
National Eye Institute logo.

NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).
National Eye Institute logo.

Older Treatment May Be More Effective in Preserving Sight for Some Patients with Diabetes

A promising new drug therapy used to treat abnormal swelling in the eye-a condition called diabetic macular edema-proved less effective than traditional laser treatments in a study funded by the National Eye Institute (NEI), part of the NIH.
Fundus photograph of age-related macular degeneration showing drusen.

Vision Not Improved By Surgery for Complications of Age-Related Macular Degeneration

Vision does not improve substantially for patients with age-related macular degeneration (AMD) who undergo surgery to remove lesions of new blood vessels, scar tissue, or possible bleeding beneath the retina.
National Eye Institute logo.

New Eye Disease Treatment May Improve Patients' Quality of Life

In a small preliminary study, researchers at the National Institutes of Health (NIH) have discovered a possible new treatment for uveitis, a potentially blinding eye disease.

Want more news from NEI?

Subscribe to our news feed to stay up to date on vision and eye health research!

Success! Link copied to clipboard.

Copy to clipboard failed.

You can also browse older stories in our news archive

NEI Press Office

We can connect media professionals with the latest vision research info. Get in touch!


Phone: 301-496-5248